Prithviraj Bose, MD:We have a 58-year-old woman at The University of Texas MD Anderson Cancer Center presenting with some abdominal pain, dizziness, and headaches; blood pressure is a little elevated, just mildly; a slightly enlarged spleen. She’s never had a clot. Hemoglobin count is elevated at 17.1 g/dL. The white blood cell count is elevated as well, 13.2. The EPO [erythropoietin] level is conspicuously low. Bone marrow shows erythroid hyperplasia, and she has aJAK2mutation.
So here we have a lady who pretty clearly has PV [polycythemia vera]. You see that her hemoglobin count is higher than the WHO [World Health Organization] thresholds. She has a low EPO level. She has aJAK2V617Fmutation. She has a bone marrow that’s typical with the erythroid hyperplasia. She has pancytosis with her white blood cell count being elevated as well, so it’s a pretty clear-cut case of PV.
Transcript edited for clarity.
Case: 58-Year-Old Woman Diagnosed With Polycythemia Vera
November 2018
Rossetti Reviews Myelofibrosis Risk Stratification and Outcome Data for Pacritinib
July 17th 2024During a Case-Based Roundtable® event, James M. Rossetti, DO, discussed the role of risk scoring and stratification tools and treatment for a patient with declining hemoglobin and platelet counts due to primary myelofibrosis.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
Ruxolitinib Treatment in Myelofibrosis Still Effective, Regardless of Anemia
June 21st 2024New or worsening anemia did not appear to reduce the clinical benefit of ruxolitinib in myelofibrosis patients, and the median overall survival was similar between patients with and without new or worsening anemia.
Read More
Challenging Disease Features of Myelofibrosis Lead to Use of JAK Inhibitors
June 17th 2024During a Case-Based Roundtable® event, Kristen Pettit, MD, moderated a discussion on which disease features of myelofibrosis are most challenging and when to use JAK inhibitors in the first article of a 2-part series.
Read More